Immunoglobulin‐like transcript 2 blockade restores antitumor immune responses in glioblastoma.
- Published in:
- Cancer Science, 2023, v. 114, n. 1, p. 48, doi. 10.1111/cas.15575
- By:
- Publication type:
- Article
Works by Martínez-Pérez, Alejandra
Results: 6
1
2
Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.
- Published in:
- Molecular Cancer, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12943-023-01845-4
- By:
- Publication type:
- Article
3
Correction: Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
4
Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements.
- Published in:
- Biomarker Research, 2024, v. 12, n. 1, p. 1, doi. 10.1186/s40364-024-00671-0
- By:
- Publication type:
- Article
5
BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 7, p. 2529, doi. 10.1007/s00262-023-03435-1
- By:
- Publication type:
- Article
6
Chemo-Immunotherapy: A New Trend in Cancer Treatment.
- Published in:
- Cancers, 2023, v. 15, n. 11, p. 2912, doi. 10.3390/cancers15112912
- By:
- Publication type:
- Article